Cargando…

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

Taxane-based chemotherapy for the treatment of breast cancer is associated with fluid retention in the extremities; however, its association with development of breast cancer-related lymphedema is unclear. We sought to determine if adjuvant taxane-based chemotherapy increased risk of lymphedema or m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swaroop, Meyha N., Ferguson, Chantal M., Horick, Nora K., Skolny, Melissa N., Miller, Cynthia L., Jammallo, Lauren S., Brunelle, Cheryl L., O’Toole, Jean A., Isakoff, Steven J., Specht, Michelle C., Taghian, Alphonse G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432026/ https://www.ncbi.nlm.nih.gov/pubmed/25940996 http://dx.doi.org/10.1007/s10549-015-3408-1

Ejemplares similares

Establishing and Sustaining a Prospective Screening Program for Breast Cancer-Related Lymphedema at the Massachusetts General Hospital: Lessons Learned
por: Brunelle, Cheryl, et al.
Publicado: (2015)

A retrospective analysis of commonly prescribed medications and the risk of developing breast cancer related lymphedema
por: Meijer, Eelco FJ, et al.
Publicado: (2020)

Lymphoedema screening: setting the standard
por: Brunelle, Cheryl L., et al.
Publicado: (2020)

Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study)
por: Isakoff, Steven J., et al.
Publicado: (2023)

The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema
por: Winters, H., et al.
Publicado: (2017)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema
por: Kaufman, David I., et al.
Publicado: (2017)

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
por: Inoue, Kenichi, et al.
Publicado: (2016)

Correlation between patency and clinical improvement after lymphaticovenous anastomosis (LVA) in breast cancer-related lymphedema: 12-month follow-up
por: Wolfs, Joost A. G. N., et al.
Publicado: (2019)

Lymphatico-venous anastomosis as treatment for breast cancer-related lymphedema: a prospective study on quality of life
por: Cornelissen, Anouk J. M., et al.
Publicado: (2017)

Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging
por: Aldrich, Melissa B., et al.
Publicado: (2022)

Combining reconstructive and ablative surgical treatment of chronic breast cancer-related lymphedema (BCRL): safe and effective
por: Ghazaleh, Alina A., et al.
Publicado: (2022)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Outcomes following lymphaticovenous anastomosis (LVA) for 100 cases of lymphedema: results over 24-months follow-up
por: Qiu, Shan S., et al.
Publicado: (2020)

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
por: Fukada, Ippei, et al.
Publicado: (2021)

Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience
por: Yang, Eun Joo, et al.
Publicado: (2016)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements
por: Shah, Chirag, et al.
Publicado: (2020)

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
por: Pohlmann, Paula R., et al.
Publicado: (2022)

Obesity and Taxanes are Independent Risk Factors for Postmastectomy Lymphedema: A TriNetX Based Analysis
por: Eldaly, Abdullah, et al.
Publicado: (2023)

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
por: Heinzelmann-Schwarz, Viola, et al.
Publicado: (2020)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

Taxane-based chemotherapy and risk of breast cancer-related lymphedema: Protocol for a systematic review and meta-analysis
por: Zhang, Zhenhua, et al.
Publicado: (2019)

Sex Differences in Taxane Toxicities
por: Chmielewski, Nicole N., et al.
Publicado: (2022)

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
por: Xenidis, N, et al.
Publicado: (2013)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
por: Joona, Therse Björkin, et al.
Publicado: (2020)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study
por: Zhang, Lin, et al.
Publicado: (2022)

Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery
por: Lanahan, Conor R., et al.
Publicado: (2021)

Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer
por: Chen, Bihong T., et al.
Publicado: (2018)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients—a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy
por: Kuhn, Elaine P., et al.
Publicado: (2023)

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study
por: Campiglio, M., et al.
Publicado: (2013)

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program
Publicado: (2023)

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2020)

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
por: Martín, M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_992blkri1bpov4hg3osuud54tr